Celldex Therapeutics, Inc. Proceeds from Common Stock Issued
Celldex Therapeutics, Inc. (CLDX) reported Proceeds from Common Stock Issued of $323.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-06
- Celldex Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- Celldex Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- Celldex Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-06-30 was $0.00.
- Celldex Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-03-31 was $432.30M.
- Celldex Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2024 was $432.30M, a 99.93% increase from fiscal 2023.
- Celldex Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2023 was $216.22M.
- Celldex Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2021 was $269.89M, a 58.02% increase from fiscal 2020.
- Celldex Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2020 was $170.79M, a 951.16% increase from fiscal 2019.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2026-06-30 | $323.83M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $432.30M 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $432.30M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $432.30M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $432.30M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $216.22M 10-K · filed 2026-02-25 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $269.89M 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $269.89M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | -$172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.13M derived: sum of 2 quarters · filed 2023-02-28 | $169.18M derived: sum of 3 quarters · filed 2023-02-28 | $170.79M 10-K · filed 2023-02-28 |
| 2020-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $169.35M derived: sum of 2 quarters · filed 2021-11-09 | $170.96M 10-Q · filed 2021-11-09 | $173.39M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $165.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $166.67M 10-Q · filed 2021-08-05 | $169.09M derived: sum of 3 quarters · filed 2022-02-28 | $171.55M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.61M 10-Q · filed 2021-05-06 | $4.04M derived: sum of 2 quarters · filed 2022-02-28 | $6.50M derived: sum of 3 quarters · filed 2022-02-28 | $13.71M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.88M derived: sum of 2 quarters · filed 2022-02-28 | $12.10M derived: sum of 3 quarters · filed 2022-02-28 | $16.25M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $9.68M derived: sum of 2 quarters · filed 2020-11-05 | $13.83M 10-Q · filed 2020-11-05 | $17.39M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-06-30 | $7.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $11.36M 10-Q · filed 2020-08-06 | $14.93M derived: sum of 3 quarters · filed 2021-03-29 | $20.43M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-03-31 | $4.15M 10-Q · filed 2020-05-06 | $7.72M derived: sum of 2 quarters · filed 2021-03-29 | $13.21M derived: sum of 3 quarters · filed 2021-03-29 | $21.48M derived: sum of 4 quarters · filed 2021-03-29 |
| 2018-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $9.06M derived: sum of 2 quarters · filed 2021-03-29 | $17.33M derived: sum of 3 quarters · filed 2021-03-29 | $29.02M 10-K · filed 2021-03-29 |
| 2018-09-30 | $5.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $13.76M derived: sum of 2 quarters · filed 2019-11-12 | $25.45M 10-Q · filed 2019-11-12 | $43.84M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $8.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $19.96M 10-Q · filed 2019-08-07 | $38.34M derived: sum of 3 quarters · filed 2020-03-26 | $49.50M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | $11.69M 10-Q · filed 2019-05-07 | $30.07M derived: sum of 2 quarters · filed 2020-03-26 | $41.23M derived: sum of 3 quarters · filed 2020-03-26 | $49.89M derived: sum of 4 quarters · filed 2020-03-26 |
| 2017-12-31 | $18.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $29.54M derived: sum of 2 quarters · filed 2020-03-26 | $38.20M derived: sum of 3 quarters · filed 2020-03-26 | $51.02M 10-K · filed 2020-03-26 |
| 2017-09-30 | $11.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $19.82M derived: sum of 2 quarters · filed 2018-11-07 | $32.64M 10-Q · filed 2018-11-07 | $35.92M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $8.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $21.49M 10-Q · filed 2018-08-08 | $24.77M derived: sum of 3 quarters · filed 2019-03-07 | $32.88M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $12.82M 10-Q · filed 2018-05-10 | $16.10M derived: sum of 2 quarters · filed 2019-03-07 | $24.22M derived: sum of 3 quarters · filed 2019-03-07 | |
| 2016-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $11.39M derived: sum of 2 quarters · filed 2019-03-07 | $13.95M 10-K · filed 2019-03-07 | |
| 2016-09-30 | $8.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $10.67M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $2.55M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $0.00 derived: sum of 2 quarters · filed 2018-03-07 | $66.00K derived: sum of 3 quarters · filed 2018-03-07 | $188.84M 10-K · filed 2018-03-07 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $66.00K derived: sum of 2 quarters · filed 2016-11-07 | $188.84M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $188.84M 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | $188.77M 10-Q · filed 2016-05-05 | |||
| 2013-12-31 | $181.51M derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-02-25 | $181.51M derived: sum of 2 quarters · filed 2016-02-25 | $181.51M derived: sum of 3 quarters · filed 2016-02-25 | $295.70M 10-K/A · filed 2016-02-25 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $0.00 derived: sum of 2 quarters · filed 2014-11-05 | $114.19M 10-Q · filed 2014-11-05 | $135.10M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $114.19M 10-Q · filed 2014-08-07 | $135.10M derived: sum of 3 quarters · filed 2015-02-24 | $146.01M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $114.19M 10-Q · filed 2014-05-01 | $135.10M derived: sum of 2 quarters · filed 2015-02-24 | $146.01M derived: sum of 3 quarters · filed 2015-02-24 | $146.04M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $20.91M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $31.83M derived: sum of 2 quarters · filed 2015-02-24 | $31.86M derived: sum of 3 quarters · filed 2015-02-24 | $83.78M 10-K · filed 2015-02-24 |
| 2012-09-30 | $10.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $10.94M derived: sum of 2 quarters · filed 2013-11-08 | $62.87M 10-Q · filed 2013-11-08 | $63.02M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $51.96M 10-Q · filed 2013-08-06 | $52.10M derived: sum of 3 quarters · filed 2014-03-03 | $52.09M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | $51.93M 10-Q · filed 2013-05-03 | $52.07M derived: sum of 2 quarters · filed 2014-03-03 | $52.06M derived: sum of 3 quarters · filed 2014-03-03 | |
| 2011-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $134.00K derived: sum of 2 quarters · filed 2014-03-03 | $36.02M 10-K · filed 2014-03-03 | |
| 2011-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $35.88M 10-Q · filed 2012-11-02 | ||
| 2011-06-30 | $35.89M 10-Q · filed 2012-08-09 | |||
| 2010-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $398.00K derived: sum of 2 quarters · filed 2013-03-08 | $1.01M 10-K · filed 2013-03-08 | |
| 2010-09-30 | $385.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $1.00M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | $616.00K 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $668.00K 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |